PALO ALTO, Calif., Aug. 19, 2014 /PRNewswire/ -- Cellular Research announced today the start of an early access program for its Precise(TM) assays and is currently making the product available to 10 sites.
The Precise assays provide ultra-sensitive RNASeq assay technology designed to examine large numbers of standard or low input mRNA samples in high throughput. Based on Cellular Research's Molecular Indexing(TM) technology, the assays provide the highest accuracy and precision available and are designed for rare and precious samples or whenever absolute quantitation is required. The Precise assays combine molecular and sample indexing in 96 and 384 sample formats, enabling customers to sequence up to 2,000 samples on one sequencing run without investment in new equipment or extensive training. The assays deliver unprecedented accuracy and sensitivity for low expression targets in rare and low quantity samples. Combined with robust design and data analysis pipelines the assays deliver a simple turnkey solution for targeted RNASeq experiments. Early access customers may start with a list of genes in which they are interested, and Cellular Research will generate the specific panel of assays for them.
Several high profile research and commercial customers have validated the assays and additional interested users should contact Cellular Research. Data from the early access program will be used to further validate the performance of the assays and optimize assay design and experimental analysis.
"The Precise assays the next in a series of products developed by Cellular Research and represent a key step in our goal of enabling high throughput and high resolution genomics," said Steve Fodor Ph.D., Chief Executive Officer of Cellular Research. "These assays are highly reproducible, and we are using our unique Molecular Indexing technology to allow precise quantitation of each mRNA transcript," Fodor concluded.
In conjunction with the Precise assay, Cellular Research is collaborating with Seven Bridges Genomics (SBG) to offer customers a complete analysis pipeline, which provides an integrated cloud-based data platform for management, execution and collaboration of the RNASeq experiments in a robust, easy-to-use informatics platform.
"The Seven Bridges Genomics (SBG) Platform provides an integrated cloud computing environment to manage, execute and collaborate on all aspects of NGS analysis workflows. SBG is proud to work with Cellular Research to provide their customers with a robust and easy to use workflow which meets CR's specifications and executes on the Seven Bridges Platform," said CEO Deniz Kural.
About Cellular Research, Inc.
Cellular Research, Inc. is a biotechnology research and development company founded by innovators from Silicon Valley and Stanford University whose mission is to develop revolutionary quantitative biology products. In addition to the Precise Assays, Cellular Research has developed and is currently offering The Pixel system, a standalone direct mRNA quantitation platform. For more information, please visit www.cellular-research.com
About Seven Bridges Genomics:
With over 80 employees in 3 locations worldwide, Seven Bridges Genomics is the leading provider of a secure, cloud-delivered platform that enables subscribers to design and execute complex next generation sequencing data analysis pipelines without the burdens of do-it-yourself command line bioinformatics. Our comprehensive and intuitive data exploration tools help you solve big data analytics problems with ease. The Seven Bridges Platform was the first of its kind to be publicly available and currently offers researchers over 300 open-source applications and custom designed tools to advance genomic analysis. For more information, please visit www.sbgenomics.com
Martin Pieprzyk, Director Strategic Marketing
SOURCE Cellular Research, Inc.